Alkermes Remains Committed to Oncology Innovation

Jun 21, 2022 12:15 PM ET

On the heels of ASCO22, we remain committed to innovating in the oncology space, particularly for cancers with high unmet needs, like platinum-resistant ovarian cancer. Thomas Herzog, M.D. and Craig Hopkinson M.D. share their insights on how our actively recruiting ARTISTRY-7 clinical trial in platinum-resistant ovarian cancer aspires to address these needs: